New insights into the role of TREM2 in Alzheimer's disease

Maud Gratuze, Cheryl E.G. Leyns, David M. Holtzman

Research output: Contribution to journalReview article

38 Scopus citations

Abstract

Alzheimer's disease (AD) is the leading cause of dementia. The two histopathological markers of AD are amyloid plaques composed of the amyloid-β (Aβ) peptide, and neurofibrillary tangles of aggregated, abnormally hyperphosphorylated tau protein. The majority of AD cases are late-onset, after the age of 65, where a clear cause is still unknown. However, there are likely different multifactorial contributors including age, enviornment, biology and genetics which can increase risk for the disease. Genetic predisposition is considerable, with heritability estimates of 60-80%. Genetic factors such as rare variants of TREM2 (triggering receptor expressed on myeloid cells-2) strongly increase the risk of developing AD, confirming the role of microglia in AD pathogenesis. In the last 5 years, several studies have dissected the mechanisms by which TREM2, as well as its rare variants affect amyloid and tau pathologies and their consequences in both animal models and in human studies. In this review, we summarize increases in our understanding of the involvement of TREM2 and microglia in AD development that may open new therapeutic strategies targeting the immune system to influence AD pathogenesis.

Original languageEnglish
Article number66
JournalMolecular neurodegeneration
Volume13
Issue number1
DOIs
StatePublished - Dec 20 2018

Keywords

  • Alzheimer's disease
  • ApoE
  • Gliosis
  • Microglia
  • Neurodegeneration
  • TREM2

Fingerprint Dive into the research topics of 'New insights into the role of TREM2 in Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this